Canaccord Genuity Maintains a 'Hold' on Celgene (CELG); Big Revlimid Regulatory Catalyst Ahead

Canaccord Genuity maintains a 'Hold' on Celgene (NASDAQ: CELG) price target raised from $66 to $71.

Analyst, George Farmer, said, "We maintain our rating on CELG shares on our view of priced-in growth expectations and headline risk from ongoing FDA review of Revlimid second primary malignancy (SPM) signals. We see no need to rush in at current trading levels."

For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.

Shares of Celgene closed at $72.66 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Canaccord Downgrades York Space Systems (YSS) to Hold, 'Supply chain and contract timing uncertainty'
• Stifel on Bally's Corp (BALY): 'expect shares to continue to trade mainly on development project cost & financing updates'
• Deutsche Bank Downgrades Workday (WDAY) to Hold